Biogaia's Reuteri reduces the level of helicobacter pylori infection
New data is emerging from clinical trials suggesting a role for Reuteri as an aid in the treatment of Helicobacter pylori infected adults and children. Helicobacter pylori can cause gastric ulcers and long term infections can cause stomach cancer. These findings clearly indicate that BioGaia´s probiotic Reuteri can reduce the level of H. pylori infection, alleviate gastrointestinal symptoms caused by the H. pylori infection and reduce side effects of antibiotic treatment.
Dr Ruggiero Francavilla and colleagues from the University of Bari, Italy presented a study on 20 adults infected by H. pylori with symptoms who were blindly randomised to receive either Reuteri or placebo for 28 days. They found a significant decrease in the level of H. pylori infection coupled to a significant improvement in gastrointestinal symptoms (abdominal pain, reflux, indigestion, diarrhoea and constipation) with Reuteri compared to placebo. They concluded that there might be a role for Reuteri supplements in the control of dyspeptic symptoms in H. pylori infected adults.
These findings confirm earlier data obtained in a clinical trial by Profe ssor Shin´ichi Takahashi at Kyorin University School of Medicine, Tokyo, Japan where a similar reduction on H-pylori levels in non-symptomatic H. pylori-infected subjects was observed.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
